Services

Delivering translational medicine solutions to Federal and health entities

Translational Medicine

Shifting to a translational approach–in which a more dynamic, integrated, and continuous process of data sharing occurs between the traditional steps in the R&D value chain–holds great opportunity for accelerating iterations of scientific discovery and development, implementing evidence in practice more efficiently and effectively, acquiring a deeper knowledge about product safety and effectiveness, and reducing overall R&D costs.

What is Translational Medicine?

Definition: Translation is the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public—from diagnostics and therapeutics to medical procedures and behavioral changes.

Source: National Center for Advancing Translational Sciences (NCATS)

 

Precision Medicine Video

Value-based care for the public sector means targeting the right drug for the right patient. Hear more from Terri Cooper, PhD, principal, Federal Health Practice leader, Deloitte Consulting LLP, discuss how precision medicine can help get the right treatments to the right patients.

Deloitte's path to 21st century cures: A call to action

A translational approach to the R&D value chain removes discrete steps and connects the discovery, development, and delivery processes. New learnings inform this value chain, and additional discoveries and developments lead to a continuous process improvement cycle. This could accelerate US life sciences R&D and bolster global competitiveness.

Read our paper Deloitte's path to 21st century cures: A call to action.

Collaboration and innovation: Ending the 17-year “valley of death” in getting treatments to patients

Today, it typically takes 17 or more years to get from the basic science stage to commercializing and introducing a new clinical product into the market.1 Innovation can be complex, but for many patients and families, this is just too long. Many stakeholders are trying to get out of this 17-year “valley of death” – federal agencies charged with protecting and improving public health, private industry facing multiple challenges in research and development (R&D) productivity, nonprofit advocacy organizations who represent patients, and many others in the research and academic community. Read about how organizations are using four key accelerator areas to achieve milestones.

Read the complete “My Take” on Collaboration and innovation: Ending the 17-year “valley of death” in getting treatments to patients.
 

Leveraging benefit-risk information to achieve better outcomes

As stakeholders in the health care industry are incentivized to be accountable to each other and patients, innovation can be revitalized, research synergies can emerge and collaboration can be centralized. Decisions around benefits and risks will no longer play an ancillary role in health care; instead, it will be a driver for pivotal decisions that are made with patient outcomes at the epicenter.

Read our paper Transitional medicine:State of the industry report.

The Ebola outbreak: A call to action for a translational approach to R&D

Traditionally, the research and development (R&D) processes within the life sciences value chain–discovery, development, and delivery–have occurred in silos with limited sharing of data and effective practices from one step to the next, and little or slow looping back to earlier phases with insights and information that might inform future iterations of improvement and innovation at each stage. Shifting to a translational approach–in which a more dynamic, integrated, and continuous process of data sharing occurs between the traditional steps in the R&D value chain–holds great opportunity for accelerating iterations of scientific discovery and development, implementing evidence in practice more efficiently and effectively, acquiring a deeper knowledge about product safety and effectiveness, and reducing overall R&D costs.​

Read our blog on The Ebola outbreak: A call to action for a translational approach to R&D.

Executing an open innovation model

Cooperation is key to competition for biopharmaceutical companies

Biopharma companies’ reliance on a traditional, closed R&D model might stifle true innovation. However, companies that adopt a cooperative, open innovation framework are likely to spur product development, speed time to market, reduce costs, and increase competitiveness.

Download PDF

21st Century Cures: Revolutionizing the launch of new therapies

In my opinion, one of the most exciting and promising aspects of 21st Century Cures is the precision medicine initiative. Precision medicine involves tailoring medical treatment to the individual characteristics of each patient. It results in an individualized approach that takes into account variability in genes, environment and lifestyle.​

Read our “My Take”  21st Century Cures: Revolutionizing the launch of new therapies.

Wicked opportunities

“Wicked problems”—ranging from malaria to dwindling water supplies—are being reframed as “wicked opportunities” and tackled by networks of non-governmental organizations, social entrepreneurs, governments, and big businesses.

Read about Wicked opportunities.

Precision medicine: Bridging the gap between potential and reality

Twenty-six years ago, researchers announced they had discovered the gene that causes cystic fibrosis (CF).1 Just three years ago, the US Food and Drug Administration (FDA) approved Ivacaftor (Kalydeco™), the first drug to target the underlying cause of CF: a faulty gene and its protein product. KalydecoTM is now approved for use in about 10 percent of patients who have particular genetic mutations. Though there is more work to be done to develop targeted therapies for patients with CF, the discovery of the gene and the decades-long quest for a targeted, effective treatment is a precision medicine success story.

Read our “My Take” on Precision medicine: Bridging the gap between potential and reality.

Meet the leaders

Terri Cooper

Terri Cooper

Deloitte's Chief Inclusion Officer

Dr. Terri is currently Deloitte’s Chief Inclusion Officer, global sector leader for Health Care, and the US national chief inclusion officer for Deloitte Consulting LLP. Terri has a personal passion a... More

Beth Meagher

Beth Meagher

Federal Strategy Leader | Deloitte Consulting LLP

Beth is a Deloitte Consulting LLP principal and leader of the Federal Strategy and Translational Medicine practices. Beth focuses on helping the Federal government transform how it views customers; le... More

Asif Dhar

Asif Dhar

Principal | Deloitte Consulting LLP

Asif is a principal in Deloitte Consulting LLP's Monitor Deloitte practice. He serves as Chief Health Informatics Officer (CHIO) and helps drive the Therapeutic Area Transformation Integrated offering... More